BRIEF—SSB and Immunochina to collaborate in bioproduction

The Chinese business of German biopharma supplier Sartorius Stedim Biotech (SSB) has partnered with Beijing-based Immunochina Pharmaceuticals in a new collaboration.

Under the terms of the deal, Immunochina will gain “preferred access” to SSB’s bioprocess technology platform for development, scale-up and production.

The firm will also gain access to new cellular immunotherapy production equipment and related commercial-scale manufacturing expertise.

SSB aims to provide biotech companies with “total bioprocess technology solutions.”